• MaxCyte to Participate in Baird Global Healthcare Conference

    来源: Nasdaq GlobeNewswire / 05 9月 2023 08:05:00   America/New_York

    ROCKVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the Baird Global Healthcare Conference on Wednesday, September 13th at 2:35 p.m. Eastern Time.

    A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

    About MaxCyte

    At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

    MaxCyte Contacts:

    US IR Adviser 
    Gilmartin Group 
    David Deuchler, CFA 
    +1 415-937-5400 
    ir@maxcyte.com  

    US Media Relations 
    Spectrum Seismic Collaborative 
    Valerie Enes 
    +1 408-497-8568 
    valerie@spectrumscience.com  

    Nominated Adviser and Joint Corporate Broker 
    Panmure Gordon 
    Emma Earl / Freddy Crossley 
    Corporate Broking 
    Rupert Dearden 
    +44 (0)20 7886 2500 

    UK IR Adviser 
    Consilium Strategic Communications 
    Mary-Jane Elliott 
    Chris Welsh 
    +44 (0)203 709 5700 
    maxcyte@consilium-comms.com 


    Primary Logo

分享